Table 1.
Indication | Responders | Specifications | ||
---|---|---|---|---|
2005 (n = 19) | 2015 (n = 8) | 2005 | 2015 | |
Lymph node metastasis | 12/19 (63 %) | 8/8 (100 %) | ≥N2b, levels, IV–V, supraclavicular | See Table 2 |
Extremely mutilating surgical intervention | 11/19 (58 %) | 5/8 (63 %) | ||
Local and/or regional recurrence | 9/19 (47 %) | 4/8 (50 %) | ||
T-stage 3–4 | 6/19 (32 %) | 1/8 (13 %) | ||
Second primary head and neck cancer | 4/19 (21 %) | 3/8 (38 %) |